Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Schmidt

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Current Topics in Medicinal Chemistry|February 20, 2010
Phosphodiesterase inhibitors as potential cognition enhancing agentsChristopher J Schmidt
Current Opinion in Otolaryngology & Head and Neck Surgery|July 13, 2006
Cosmetic dentistryChristopher J Schmidt, Sherard A Tatum
Frontiers in Neuroscience|September 12, 2019
Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-OxideJohn F Harms, Frank S Menniti, Christopher J Schmidt
Frontiers in Neuroscience|February 8, 2021
PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?Frank S Menniti, Thomas A Chappie, Christopher J Schmidt
Nature Reviews. Drug Discovery|August 3, 2006
Phosphodiesterases in the CNS: targets for drug developmentFrank S Menniti, W Stephen Faraci, Christopher J Schmidt
Current Opinion in Investigational Drugs (London, England : 2000)|February 1, 2007
Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophreniaFrank S Menniti, Thomas A Chappie, John M Humphrey, et al.
Brain, Behavior, and Immunity|April 26, 2017
The isozyme selective phosphodiesterase-4 inhibitor, ABI-4, attenuates the effects of lipopolysaccharide in human cells and rodent models of peripheral and CNS inflammationJoseph R Hedde, Ashley N Hanks, Christopher J Schmidt, et al.
Psychopharmacology|December 24, 2013
Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gatingJodi E Gresack, Patricia A Seymour, Christopher J Schmidt, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 6, 2008
Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical StimulationSarah Threlfell, Stephen Sammut, Frank S Menniti, et al.
Journal of Neuroscience Methods|February 20, 2013
Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scaleSubramaniam Uthayathas, Christopher L Shaffer, Frank S Menniti, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Current Topics in Medicinal Chemistry|February 20, 2010
Phosphodiesterase inhibitors as potential cognition enhancing agentsChristopher J Schmidt
Current Opinion in Otolaryngology & Head and Neck Surgery|July 13, 2006
Cosmetic dentistryChristopher J Schmidt, Sherard A Tatum
Frontiers in Neuroscience|September 12, 2019
Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-OxideJohn F Harms, Frank S Menniti, Christopher J Schmidt
Frontiers in Neuroscience|February 8, 2021
PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?Frank S Menniti, Thomas A Chappie, Christopher J Schmidt
Nature Reviews. Drug Discovery|August 3, 2006
Phosphodiesterases in the CNS: targets for drug developmentFrank S Menniti, W Stephen Faraci, Christopher J Schmidt
Current Opinion in Investigational Drugs (London, England : 2000)|February 1, 2007
Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophreniaFrank S Menniti, Thomas A Chappie, John M Humphrey, et al.
Brain, Behavior, and Immunity|April 26, 2017
The isozyme selective phosphodiesterase-4 inhibitor, ABI-4, attenuates the effects of lipopolysaccharide in human cells and rodent models of peripheral and CNS inflammationJoseph R Hedde, Ashley N Hanks, Christopher J Schmidt, et al.
Psychopharmacology|December 24, 2013
Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gatingJodi E Gresack, Patricia A Seymour, Christopher J Schmidt, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 6, 2008
Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical StimulationSarah Threlfell, Stephen Sammut, Frank S Menniti, et al.
Journal of Neuroscience Methods|February 20, 2013
Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scaleSubramaniam Uthayathas, Christopher L Shaffer, Frank S Menniti, et al.
Pageof 5